Background: The long-term survival of patients with advanced stage aggressive lymphoma has not improved significantly during the last twenty years. In a randomised trial, the efficacy of MACOP-B, a six-drug weekly chemotherapy regimen, was compared to CHOP, the current standard regimen, in terms of overall and failure-free survival, toxicity and health related quality of life.
Introduction
Since the introduction of the first doxorubicin-containing regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), in 1976 [1] , advanced stage aggressive lymphoma has been a potentially curable disease with a long term survival rate around 30%-40%. However, results have not improved significantly over the following twenty years. Goldie and Coldman [2] proposed that early introduction of as many active drugs as possible in a treatment schedule would circumvent drug resistance and improve treatment results. In accordance with this hypothesis, the MACOP-B regimen (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) was introduced. This 12-week, 6-drug regimen provided higher dose intensity regarding doxorubicin and vincristine, continuous corticosteroid administration, and two additional non cross-resistant drugs, bleomycin and methotrexate. In the original report [3] , the CR rate was 84%, and two year overall survival rate was 75%. In therapy trials with curative intent, measurements of health-related quality of life (HRQOL) may be of significant importance, especially when small differences in therapeutic efficacy are expected. It has been shown during the last decade, that measures of HRQOL may give important additional information in studies focusing on life prolongation [4] , palliation [5] , during highly intensive curative treatment [6] and in order to identify late morbidity after curative treatment [7] . Based upon these considerations, in 1989 the Nordic Lymphoma Group initiated a randomised multicentre trial to compare the MACOP-B regimen with CHOP. Survival was the primary endpoint, with response, failure-free survival, toxicity and HRQOL as secondary endpoints.
the updated Kiel classification (centroblastic, immunoblastic, anaplastic large cell and peripheral T-cell lymphoma) and stage II-IV. Patients with central nervous system (CNS) involvement, concurrent low-grade (discordant) lymphoma, Burkitt's or Burkitt-like lymphoma or lymphoblastic lymphoma were excluded. All patients gave informed consent and ethics committee approval was obtained in all participating regions. Staging procedures included physical examination, routine blood chemistry tests including serum lactate dehydrogenase (S-LDH). bone marrow biopsy and smear, chest X-ray and computerised tomography (CT) of abdomen and pelvis. All patients' records were reviewed by a panel from the Nordic Lymphoma Group, and all histopathological specimens were reviewed *by a board of hematopathologists, and classified according to the updated Kiel Classification [8] and the Revised European-American Lymphoma (R.E.A.L.) Classification [9] . Diagnosis at review was based on surgical biopsies with standard hemaloxyhn-eosin and Giemsa stains, supplemented by anti-CD20, anti-CD3. and anti-CD45RO immunohistochemistry. In five cases, diagnosis was based on fine needle aspiration in combination with immunophenotyping by flow cytometry Cases with non-lymphoid tumours, non-eligible lymphoma subtypes or CNS involvement are excluded from the main analysis. However, since the staging of all patients was reviewed after randomisation (below), cases classified as stage I at review are included.
Endpoints and study design
The study was organised as a phase III, multicentre randomised trial, involving hospitals in Norway and Sweden from nine health care regions. Overall survival was defined as time from randomisation to death, regardless of cause Failure-free survival was defined according to Dixon et al. [10] , i.e., as time from randomisation to progression, relapse or treatment-related death. Complete remission (CR) was defined as the complete disappearance of all palpable lesions or radiological abnormalities, maintained for at least one month after completion of therapy. In patients with a residual abnormality at the site of previous tumour, cytological or histological evidence of viable tumour was sought. However, even if a surgical or needle biopsy of the residual mass was without viable tumour, it was classified as a partial remission (PR).
International Prognostic Index
The International Prognostic Index (IPI) [II] consists of five factors: age. serum lactate dehydrogenase (LDH) level, performance status, stage and number of extranodal sites. The age-adjusted IPI, applicable for patients < 6 0 years, is a sum of three factors: LDH level, performance status and stage. With regard to stage and number of extranodal sites, the following definitions were applied. Extranodal sites includes only extralymphatic sites (i.e., not Waldeyer's ring, spleen or thymus [12]). and does not include sites involved through contiguous growth. Primary nodal disease was staged according to the original Ann Arbor criteria [13] .
Staging of extranodal disease
During the monitoring of the patients" records it was noted that principles for staging varied between different centres, especially in reference to extranodal disease. Prompted by these experiences, a working committee was founded within the Nordic Lymphoma Group to establish uniform staging criteria. All cases were subsequently restaged according to the following: Localised involvement of extranodal tissue by continuous or per continuitatem growth from an involved lymph node was defined as extension (E). To a\oid confusion, the suffix E was not used to denote primary extranodal lymphomas. For this group, we propose the use of the prefix Pe (Primary extranodal) ( Table 1) . Extranodal disease was classified according to the proposal by Musshoff [14] . modified by the Nordic Lymphoma Group, as stage Pe I in case of primary involvement of one extranodal organ or 
Chemo-and radiotherapy
CHOP and MACOP-B were administrated as described in the original reports of these regimens. Patients with bone marrow or skeletal involvement underwent CNS prophylaxis with intrathecal methotrexate 12 mg total dose in the six first courses of chemotherapy In the calculation of received dose intensity (DI) (mg/m 2 /week) the total dose of administered drug was divided by body surface area and the total number of weeks of treatment [15] . Relative DI was defined as received DI divided by projected DI for each drug.
Patients in the MACOP-B arm received infection proph>laxis with cotrimoxazole and amphotericin B or fluconazole throughout the treatment. Prophylactic antibiotics were not routinely given in the CHOP arm. After four courses of CHOP or six weeks of MACOP-B. and one month after completion of chemotherapy, a response evaluation was performed, repeating all previously abnormal investigations. Postchemotherapeutic radiotherapy was given according to the decision of the clinician. The study protocol stated that radiotherapy should only be given to residual masses that were positive by biopsy or not biopsied.
Quality of life assessment
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (vl.O) [16] . was employed, which includes five scales involving different aspects of patient functioning, nine scales related to specific symptoms, and finally a scale addressing global health and quality of life (QoL). To the QLQ-C30. a module was added, that included items concerning lymphoma and treatment specific symptoms. Before start of chemotherapy, a questionnaire was completed by the patient in the hospital. At nine subsequent measurement points, 6-56 weeks after entering the study, the questionnaire was mailed to the patients by the registration office. Quality of life scales were calculated according to the EORTC Scoring Manual [17] , and raw scores were standardised by linear transformation into ranges from 0 to 100. For the functional scales and the global QoL scale, a higher score represents a better level of function. For the symptom scales, a higher score corresponds to a higher level of symptoms.
Statistical methods
Patient characteristics, response rates and toxic reactions were compared by chi-square tests. Survival curves were estimated according to the method of Kaplan and Meier, and compared by log-rank tests. With small numbers, the exact log-rank test was used. Multivariate analysis of overall and failure-free survival was performed by Cox regression, and Mann-Whitney's U-test was used to compare dose intensity in different groups. In the quality of life study, missing data were imputed according to the EORTC Scoring Manual [17] Comparisons of quality of life scores between groups of patients were performed using Mann-Whitney U-tests and since many comparisons were done, a P-value of < 0.01 was considered necessary for statistical significance. Two-sided tests were used in all calculations.
Results

Patient characteristics
Patient demographics were similar in the two treatment groups (Table 2) , except for stage I, with more cases in the CHOP group. The median age was 51 years in the CHOP group (range 18-67) and 52 in the MACOP-B group (range 21-67). According to the IPI, 52% were 'low risk', 28% were 'low intermediate risk', 13% 'high intermediate' and 7% 'high risk'. The majority of patients (80%) were below 60 years of age, and when grouped according to the age-adjusted IPI, 25% were 'low risk', 38% 'low intermediate', 30% 'high intermediate' and 6% 'high risk'. Median time of follow-up for those still alive is at present 57 months.
Histopathology and eligibility
After histopathological review, the original diagnosis was revised in 76 cases (19%). Fifty-four cases were classified into a different high-grade lymphoma category (Kiel), compared to the original diagnosis. Classified according to Kiel, 244 (65%) were centroblastic, and only a few cases of immunoblastic (three) or anaplastic large B-cell lymphoma (two) were identified. According to the R.E.A.L. Classification, the majority, 260 (70%) were diffuse large cell B-lymphoma (DLBL). Fourteen cases (4%), including intestinal and angioimmunoblastic subtypes, were classified as peripheral T-cell lymphoma (PTCL). Thirty-six cases of anaplastic large cell lymphoma,^ or null cell (ALC) were included (10%).
Of a total number of 405 patients, 31 patients were ineligible. Two patients presented with CNS involvement. Twelve cases were classified as non-lymphoid tumours (five cases of acute myeloid leukaemia; one osteosarcoma; one seminoma, five undifferentiated carcinomas). Ten were found to belong to non-eligible lymphoma categories, and in seven cases, the biopsy material was insufficient for diagnosis. All these patients were excluded from the main efficacy analysis.
Chemotherapy
Calculation of received and relative DI could be performed in 234 of 253 cases treated in Sweden, from data extracted from the patients' records. Dose intensity data from Norwegian records were not available. CHOP and 271 with MACOP-B, corresponding to a relative DI of 0.95 and 0.96, respectively.
Response
The rate of CR was 37% in the CHOP group and 41% in the MACOP-B group (N.S) ( Table 3 ). The figures were the same when all 405 randomised patients were included. Among partially responding patients (PR), in 66 of 151 cases (44%), a biopsy was performed, either a surgical, fine needle, or tru cut biopsy. Radiotherapy (XRT) was given after response evaluation to 9 of 146 patients in CR (6%), 9 of 43 patients in PR with negative biopsy (21%), 31 of 85 patients in PR without biopsy (36%), and 12 of 23 in PR with a positive biopsy (52%). For the respective PR subgroups, there were no significant differences in outcome, whether XRT was given or not. Four (44%)) cases with negative biopsy who underwent irradiation relapsed, compared to 15 (44%)) without XRT For cases in PR without biopsy, the respective figures were 9 (29%) with XRT and 25 (46%) without. All cases in PR with positive biopsy eventually progressed. There was no difference between the two treatment groups in the use of additional XRT, 43 of 181 in the MACOP-B arm and 41 of 193 in the CHOP arm.
Overall and failure-free survival
There was no significant difference in overall or failurefree survival between patients treated with CHOP or MACOP-B. At five years, estimated overall survival was 59% in the CHOP group and 60% in the MACOP-B group (Figure 1 ). Including all 405 randomised patients, projected five-year survival was 59% with both regimens. Failure-free survival at five years was 44% with CHOP and 47% with MACOP-B (Figure 2 ). Categorising patients according to the IPI, we found the overall and failure-free survival rates to be consistent with the original report. In 'low-risk' patients, estimated survival was 72% at five years, compared to 31% in the 'high-risk' group. For patients below 60 years, according to the age-adjusted IPI. in the 'low-risk' group, five-year sur-
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Years from randomization vival was 79%, compared to 22% in the 'high-risk' group. In the latter group, a trend for improved overall survival was noted among patients receiving MACOP-B, 38% versus 10% in the CHOP group (P = 0.04). Overall survival was similar in patients receiving radiotherapy (56% at five years) compared to patients not irradiated (59% at five years). Also for patients achieving PR, there was no survival advantage when radiotherapy was given, five-year survival 62% with radiotherapy, 67% without. There were only single cases of immunoblastic (three) and anaplastic large cell B-lymphoma (two), and we could not demonstrate any differences in survival compared to cases with centroblastic histology. The centroblastic lymphomas were further subdivided according to morphology, but no differences in survival were noted among these subtypes. Cases with PTCL, as defined in the R.E.A.L. Classification, were associated with a sig- nificantly worse five year survival (17%) compared to DLBL (61%), also confirmed in multivariate analysis (below). In spite of small numbers, for PTCL cases, a significant difference in survival was noted between the two regimens; 3 of 10 patients with PTCL treated with MACOP-B survived, versus 0 of 4 treated with CHOP (P = 0.026). The outcome of cases with ALC was similar to that of DLBL.
In a multivariate model, LDH above the normal limit, WHO performance status >1, and PTCL histology emerged as independent adverse prognostic factors for survival (Table 4 ). Except for LDH-level, the same factors were also predictive of decreased failure-free survival. The patient population was divided into three equally sized groups according to received doxorubicin DI (< 16,16-23, and > 23 mg/m 2 /week). In the MACOP-B arm, overall survival was significantly prolonged in the highest dose intensity group (P -0.04). However, in multivariate analysis, dose intensity was of no independent prognostic value. There was no relation between outcome and cyclophosphamide DI or with doxorubicin DI in the first treatment cycle.
Treatment failure
In the CHOP group, 102 (53%) patients failed treatment either by relapse or progressive disease, compared to 93 (51%) of patients receiving MACOP-B. 168 (86%) of treatment failures occurred during the first two years after finishing chemotherapy. As second-line treatment, 17 received radiotherapy and 146 were given second-line chemotherapy. The majority (62%) of these were treated with MIME (methyl-GAG, ifosphamide, methotrexate and etoposide). Forty-two patients (23%) received highdose chemotherapy with autologous stem cell support (ABMT) and in two cases, an allogenic bone marrow transplantation (BMT) was performed. Among patients receiving ABMT, estimated survival at three years post treatment failure is 72%. Among cases with progressive disease during treatment, 2 of 39 patients are alive (follow-up: 18 and 72 months), both of which received ABMT.
Toxicity
Toxicity data were reported in 354 of 405 patients. Nonhaematological toxicity was generally more severe with MACOP-B, most notably with regard to WHO grade III-IV stomatitis, present in 33% in the MACOP-B group, versus 3% in the CHOP group. No bleomycinrelated pulmonary toxicity was noted. Treatment-related mortality was low; 1.9% with CHOP and 1.7% with MACOP-B (three patients in each group; three with septic shock, two with bowel perforation, one with intracerebral bleeding).
Quality of life
Only Norwegian centers enrolled patients in the QoL study. One hundred six patients were offered to participate. Ninety-five entered, of which three were ineligible. Among the 92 patients remaining for analysis, the median age was 46 years (range 20-66). Compliance at the different measure-points was 77%-100%. For patients in the MACOP-B group, there was a trend towards lower values of global QoL (P -0.04) and physical function (P -0.01) after 12 weeks (Figures 2a and 2b) . At 56 weeks, there were no detectable differences between the two groups regarding global QoL or the functional scales. During treatment, with MACOP-B, there was less appetite loss, but more fatigue. Beyond 12 weeks, when the MACOP-B chemotherapy was terminated, there were more symptoms of nausea and vomiting, fatigue, constipation and diarrhoea in the CHOP group, where chemotherapy was still ongoing. Among items addressed by the disease-and treatment specific module, night sweats were more pronounced in the CHOP group during treatment. During the later part of the treatment period, when MACOP-B was terminated, patients treated with CHOP also experienced more dizziness, hair loss, headache, dryness of the mouth and heartburn. Scores concerning neuropathic symptoms from feet were increased in the MACOP-B group, compared to pre treatment values, also at the last measure point at 56 weeks (P < 0.001) (Figure 3a) . Symptoms related to mucositis were also much more frequent among patients treated with MACOP-B (Figure 3b ).
Discussion
Many attempts have been made to find a chemotherapy regimen that could improve survival for patients with aggressive NHL. With a few exceptions, most randomised trials have found no significant differences between CHOP or other first generation regimens compared to second or third generation regimens [19, 20] . The EORTC Lymphoma Cooperative Group has compared a CHOPlike regimen, CHVmP (cyclophosphamide, doxorubicin, teniposide, prednisone), with CHVmP-VB [21] , where vincristine and bleomycin were added, and found the latter to be associated with prolonged survival even after long-term follow-up. One interpretation of this may be that vincristine. also included in the CHOP regimen, is an essential component. In the final analysis of the trial by the Australian-New Zealand Lymphoma Group comparing CHOP and MACOP-B, 10-year overall survival was superior in the MACOP-B group [22] . The latter study differs from the present one in that only six cycles of CHOP was administrated. In a British National Lymphoma Investigation (BNLI) report, comparing CHOP with PACEBOM [23] , a regimen very similar to MACOP-B, PACEBOM was found to be superior only in patients with stage IV disease. Similarly, in the present study, a survival advantage in favour of MACOP-B was noted among high-risk patients according to the age-adjusted International Index. Such a retrospective subgroup analysis should, however, be interpreted with caution.
With knowledge of the incidence of aggressive lymphoma in the participating regions, we estimate that approximately 40% of all possible eligible patients were included in the present trial. We confirmed the findings of previous trials comparing CHOP with different second and third generation regimens, that CHOP is similar in terms of response, overall survival and failure-free sur-vival. Due to the strict response criteria, the complete response rate in the present study was lower than in previous studies. More non-haematological toxicity in the MACOP-B group was noted, but no increase in treatment-related mortality.
In a situation with negligible differences in outcome between two chemotherapeutic regimens, differences in health related quality of life are of major interest, and has not previously been studied in aggressive lymphoma. Although restricted to a subset of the patient population, we found notable differences between the treatment groups regarding specific symptoms and side effects. Patients treated with MACOP-B also exhibited inferior physical and role function, possibly due to enhanced fatigue during the period of corticosteroid withdrawal. A trend towards deterioration in global quality of life was also noted during the later part of the MACOP-B treatment period as compared to CHOP.
A theoretical advantage of the MACOP-B regimen is the lower cumulative anthracyclin dose, 300 mg/m 2 doxorubicin, vs. 400 with CHOP, which may possibly lead to less long term cardiac toxicity, and allows for more intensive second line therapy. A second advantage is the shorter treatment period, three months, compared to six months for CHOP. The MACOP-B regimen was introduced as a dose-intensive regimen, but regarding the drugs with the steepest dose-response relationship; doxorubicin and cyclophosphamide, the increase in doxorubicin DI is modest, and for cyclophosphamide, the DI is lower compared to CHOP. Hence, the use of an increased number of drugs in an alternating fashion, as in the MACOP-B regimen, seems to lead to increased toxicity without overcoming chemotherapy resistance. Still, modifications of the original MACOP-B, such as VACOP-B, where methotrexate is substituted by etoposide, has been shown to be equally efficient but less toxic [24] , and may constitute an alternative to CHOP. In vitro, lymphoma cells demonstrate a clear dose-response relationship to cytotoxic drugs, and it seems probable that also in the clinical situation, high dose intensity would be associated with a better chance of cure, as has also been indicated in earlier studies [25, 26] . However, a high received dose intensity may only reflect a better patient performance status, and has to be analysed in a multivariate model. In our series, it was not an independent prognostic factor. In this material we were able to validate the prognostic power of the IPI. This index has been proven to be a powerful tool in predicting outcome in aggressive lymphoma. We have put particular emphasis in defining two of the factors of the index; stage and the number of extranodal sites. Since the Ann Arbor Staging Classification was not originally intended to be used for nonHodgkin's lymphoma, it may be difficult to apply in all cases, especially in extranodal lymphomas. Even in Hodgkin's disease, there are often difficulties in differentiating E-lesions from stage IV [27] . In this report, we employed a possible way of avoiding this confusion, by differentiating between extranodal involvement by contiguous growth from a nearby lymphatic organ, classified as extension (E), and disseminated, i.e., hematogenous spread to a distant organ, classified as stage IV. We also introduce prefix Pe for primary extranodal disease. In our own experience, this system has been easy to apply in all cases of lymphoma where it has been tested, and is currently being used routinely in the majority of Scandinavian centres.
The prognostic importance of different subtypes of aggressive lymphoma remains unclear. In the NonHodgkin's Lymphoma Classification Project [28] , anaplastic large cell lymphoma was shown to have a relatively favourable prognosis, independent of IPI. This could not be confirmed in our material, perhaps due to a small number of cases.
We could confirm, however, the dismal prognosis of peripheral T-cell lymphoma compared to aggressive B-cell lymphomas [29, 30] . Probably, patients with PTCL should not receive standard chemotherapy, and should, if possible, be included in trials of innovative therapy regimens. In this study, a slight survival advantage in favour of MACOP-B was noted, but the number of patients in this category is small and the results relatively poor also with this regimen.
In 'low-risk' patients, such as identified by the International Index, CHOP may still be regarded as the therapy of choice, associated with less impairment of HRQOL, and a good chance of cure. In 'high-risk' patients, however, trials of much more intensive regimens are warranted. Examples of such regimens are the mega-CHOP, as reported from Dana-Farber [31] , and the high dose sequential (HDS) therapy developed at the Istituto NazionaleTumori in Milan [32] , where the most active drugs are used at their maximally tolerable dose, supported by growth factors and stem cells. Using a risk-adapted approach may eventually lead to improved survival for this group of patients.
